Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver.
about
Natural history and treatment of hepatitis B virus and hepatitis C virus coinfectionClinical impact of occult hepatitis B virus infection in immunosuppressed patientsMolecular mechanisms underlying occult hepatitis B virus infection.Leishmania interferes with host cell signaling to devise a survival strategy.Serological and molecular expression of Hepatitis B infection in patients with chronic Hepatitis C from Tunisia, North Africa.Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapyEvolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virusOccult Hepatitis B (OBH) in Clinical Settings.Prevalence of occult hepatitis B virus in plasma and peripheral blood mononuclear cell compartments of patients with chronic hepatitis C infection in tehran-iranHepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment.Dual chronic hepatitis B virus and hepatitis C virus infection.Management of patients co-infected with HBV and HCV.Treatment of HBV/HCV coinfection.Occult hepatitis B: clinical implications and treatment decisions.Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.Hepatitis B virus DNA in sera of blood donors and of patients infected with hepatitis C virus and human immunodeficiency virus.Interferon-alpha receptor 1 mRNA expression in peripheral blood mononuclear cells is associated with response to interferon-alpha therapy of patients with chronic hepatitis C.The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors.Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails.Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.Absence of hepatitis B virus DNA in patients with hepatitis C and non-A-E hepatitis in the State of São Paulo, Brazil.Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases.Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection.In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a deletion in the PreS1 region of the viral genome.Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era.The management of chronic viral hepatitis: A Canadian consensus conference 2004.
P2860
Q24815355-88020ECE-65D0-4158-8018-29E1E0D0A0BAQ27006996-CB18EA3A-D84F-4173-89DF-B6F6B0DB336CQ27686923-D72808A9-9E2C-4B05-8C1A-D08164D5C61BQ33781265-27C8AB60-2956-410A-91B7-BFD2685C4E55Q34174479-549D28FA-490C-4A91-B64C-F2334635EF1FQ34387913-249589C2-071C-42B2-9C1E-BA4B88FA84E3Q35293895-3511961B-DBD1-4482-976A-F6B40A2E8D2BQ35667068-3E26796B-960E-4B5F-8C75-C6715AA2E5E5Q35833159-2ED31781-2A58-4D73-8ACB-A540D489E792Q36328982-87C08417-1160-4DB7-8C45-ABB0205F73D6Q37090963-CE66AEAF-C793-4EDA-B503-98F74AA7B195Q37132382-552D3A71-D892-4739-AA70-42EC55F3742BQ37466211-23304DE4-24C4-48A4-A563-B43C914397E8Q37503341-A4FA976F-F088-489F-8F77-7CC598F127A2Q37694558-3617F3CC-69BB-4198-BC80-C1037AC91927Q37798473-7B10B7D7-0346-4877-9B2F-38EB282C8C1DQ38805093-8CFB6691-F46D-483D-A9B7-3CF183BA073EQ39785613-6363D7D2-B7B2-4933-AD3F-8F2F4F97AC8DQ42460735-03BA9994-D046-406F-8E5B-71EBD963B0C3Q42746527-9FA485AE-8E16-496B-B8D2-715597B777C6Q42999454-C3E1D963-8003-4E5B-A121-87D28CAF0ED2Q45394122-A5BCDBBE-09E9-4425-9D8A-D11063A99340Q45397975-95C1C96D-80B6-4DC8-A0EF-8AFD5C019442Q45494455-D1FD55BA-17C8-49C2-A19E-7C3F40631E91Q45556738-96F3927C-3268-4A16-936B-2D6B3F823780Q45619475-BA0D5A19-1A7A-416B-BEDA-94E2C19DCE2DQ45723049-72497794-EB36-461A-BFFF-DE0D5018ABA4Q45732031-93A81F1B-97AA-4444-B4F0-D9B5F1EC3735Q54249544-9BF1EBE0-12F2-41A5-8097-26FA4F9C03B6Q55428306-83A82E7A-7A0B-43C0-AE82-4CCB1DFFAAD3
P2860
Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Co-infection by serologically- ...... gene expression in the liver.
@en
Co-infection by serologically- ...... gene expression in the liver.
@nl
type
label
Co-infection by serologically- ...... gene expression in the liver.
@en
Co-infection by serologically- ...... gene expression in the liver.
@nl
prefLabel
Co-infection by serologically- ...... gene expression in the liver.
@en
Co-infection by serologically- ...... gene expression in the liver.
@nl
P2093
P2860
P1476
Co-infection by serologically- ...... gene expression in the liver.
@en
P2093
M Moritani
M Watanabe
N Ishimura
S Hamamoto
S Ishihara
Y Kinoshita
P2860
P304
P356
10.1002/1096-9071(200103)63:3<220::AID-JMV1004>3.0.CO;2-3
P577
2001-03-01T00:00:00Z